Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(33%)

Phase Distribution

No phase data available

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Detailed Status

Completed2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Trials by Status

terminated133%

completed267%

Recent Activity

0 active trials

Showing 3 of 3

completed

Analysis of the Variation of the Retinal Vascularization After a Prolonged Effort

NCT03864380

completed

Prevalence of Age Related Macular Degeneration (ARMD) in Parkinson's Patients and Assesment of the Role of L-DOPA

NCT03415984

terminated

Evaluation of the Protective Role of the L-DOPA Against Age Related Macular Degeneration in Parkinson's Patients

NCT02863640

Clinical Trials (3)

Showing 3 of 3 trials

NCT03864380

Analysis of the Variation of the Retinal Vascularization After a Prolonged Effort

Completed

NCT03415984

Prevalence of Age Related Macular Degeneration (ARMD) in Parkinson's Patients and Assesment of the Role of L-DOPA

Completed

NCT02863640

Evaluation of the Protective Role of the L-DOPA Against Age Related Macular Degeneration in Parkinson's Patients

Terminated

All 3 trials loaded

Drug Details

Intervention Type: Varies by study
Total Trials: 3